Brian Dressen, Ph.D., who is a chemist with an extensive background in researching and assessing the degree of efficacy in new technologies, told the U.S. Food and Drug Administration Pfizer’s vaccine “failed any reasonable risk-benefit calculus in connection with children.”
The U.S. House of Representatives on Thursday unveiled the text of the Build Back Better Act, and it includes a provision to require banks to turn account information over to the IRS on accounts with $600 or more in annual transactions.
The U.S. Food and Drug Administration’s advisory panel today voted to recommend the agency allow Pfizer to amend its Emergency Use Authorization for its COVID vaccine for children 5 through 11 years old, despite a host of objections from scientists and physicians.